LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER Drug Patent Profile

Which patents cover Levofloxacin In Dextrose 5% In Plastic Container, and when can generic versions of Levofloxacin In Dextrose 5% In Plastic Container launch?

Levofloxacin In Dextrose 5% In Plastic Container is a drug marketed by Baxter Hlthcare Corp, Eugia Pharma, Fresenius Kabi Usa, Gland, Hikma Farmaceutica, Hospira, Inforlife, and Knack. and is included in eight NDAs.

The generic ingredient in LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER is levofloxacin. There are thirty-one drug master file entries for this compound. Forty-four suppliers are listed for this compound. Additional details are available on the levofloxacin profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Levofloxacin In Dextrose 5% In Plastic Container

A generic version of LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER was approved as levofloxacin by RISING on December 20^th, 2010.

Summary for LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

US Patents:	0
Applicants:	8
NDAs:	8
Finished Product Suppliers / Packagers:	8
Clinical Trials:	318
DailyMed Link:	LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER at DailyMed

Recent Clinical Trials for LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
National Institute of Allergy and Infectious Diseases (NIAID)	PHASE3
University of Virginia	PHASE3
Dr. Sardjito Hospital, Yogyakarta	PHASE4

See all LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER clinical trials

US Patents and Regulatory Information for LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Baxter Hlthcare Corp	LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER	levofloxacin	INJECTABLE;INJECTION	091397-001	Aug 8, 2013		DISCN	No	No
Hospira	LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER	levofloxacin	INJECTABLE;INJECTION	078579-003	Sep 3, 2015	AP	RX	No	No
Knack	LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER	levofloxacin	INJECTABLE;INJECTION	216164-003	Jan 29, 2024		DISCN	No	No

EU/EMA Drug Approvals for LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Chiesi Farmaceutici S.p.A	Quinsair	levofloxacin	EMEA/H/C/002789Quinsair is indicated for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.Consideration should be given to official guidance on the appropriate use of antibacterial agents.	Authorised	no	no	no	2015-03-25

Levofloxacin in Dextrose 5% in Plastic Container: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

What Are the Key Market Drivers for Levofloxacin in Dextrose 5%?

Levofloxacin, a fluoroquinolone antibiotic from the third-generation class, is widely used to treat bacterial infections. Its formulation in dextrose 5% (D5) in a plastic container addresses stability and compatibility with IV administration.

Factors influencing market growth include:

• Rising Infection Rates: An increase in respiratory, urinary tract, and skin infections sustains demand for intravenous antibiotics.
• Hospitalization Trends: Growth in hospitalization volumes, especially for immunocompromised patients, enhances IV medication utilization.
• Antibiotic Stewardship: Emphasis on targeted therapy favors formulations with proven efficacy, including levofloxacin.
• Regulatory Approvals: Launch of new formulations with improved stability or reduced side effects expand market share.

What Are Current Production and Supply Chain Trends?

• Manufacturing Arc: Major players such as Sandoz, Teva, and Hikma Pharmaceuticals produce levofloxacin in various formulations, with ongoing upgrades to manufacturing facilities to meet international standards.
• Packaging Evolution: Transition from glass bottles to plastic containers advances due to reduced breakage risk, ease of transport, and sterility benefits.
• Supply Chain Constraints: Raw material shortages, geopolitical disruptions, and pandemic-related logistics issues impact production capacity and costs.

How Does the Market Size and Regional Distribution Look?

Region	Market Size (2022, USD Million)	CAGR (2022-2027)	Notes
North America	320	4.5%	Dominated by hospital and niche specialty segments.
Europe	280	3.8%	Strict regulatory environment; high adoption rates.
Asia-Pacific	250	6.2%	Fastest growth driven by emerging markets.
Latin America	80	4.0%	Growing hospital infrastructure and healthcare access.
MEA	60	4.6%	Increasing demand in infectious disease management.

How Are Pricing and Regulatory Policies Evolving?

• Pricing Dynamics: Competitive pressures from generics drive down prices in mature markets. Brand-name formulations maintain premiums in regions with limited generic penetration.
• Regulatory Environment: Agencies like the FDA and EMA require strict validation for IV formulations, including stability, sterility, and compatibility testing.
• Reimbursement Strategies: Insurance coverage favors cost-effective formulations, influencing market penetration and margins.

What Financial Trajectory Is Expected?

• Revenue Trends: The global market estimate for levofloxacin in IV formulations is projected to grow from USD 0.7 billion in 2022 to USD 1.0 billion by 2027, at a compound annual growth rate (CAGR) of approximately 7.2%.
• Profitability Margins: Margins are influenced by production costs, patent statuses, and competitive pricing. Margins are higher for branded products initially, decreasing as generics enter markets.
• Research and Development: Investment focuses on improving stability, reducing adverse effects, and developing novel delivery systems; R&D spending is generally 10-15% of revenue.

Comparative Market Forecast

Aspect	2022 Base	2027 Projection	CAGR
Market Size (USD Million)	850	1,150	7.2%
Gross Margin (%)	45-50%	40-45%	-
R&D Investment (USD Million)	85-128	115-173	10-15%

Are There Key Regulatory or Competitive Barriers?

Yes. Challenges include:

• Patent Expirations: Many patents for levofloxacin formulations expired, increasing generic competition.
• Quality Standards: Compliance with Good Manufacturing Practices (GMP) and sterile manufacturing processes is rigorous.
• Market Saturation: Mature markets face limited growth potential without innovations or new indications.

What Are the Risks and Opportunities?

Risks

• Evolving resistance profiles, potentially reducing levofloxacin effectiveness.
• Pricing pressures due to generic competition.
• Regulatory delays or restrictions.

Opportunities

• Expanding use in emerging markets with increasing healthcare infrastructure.
• Development of combination therapies or novel stable formulations.
• Growing demand for outpatient IV therapy options.

Key Takeaways

• The global market for levofloxacin in Dextrose 5% in plastic containers is growing at a CAGR of approximately 7.2%, driven by rising infection rates and hospitalizations.
• Market growth varies regionally, with Asia-Pacific experiencing the fastest expansion.
• Price competition intensifies following patent expiry, especially in mature markets.
• R&D investments focus on improving stability, reducing side effects, and novel delivery systems.
• Supply chain disruptions and resistance development pose ongoing risks; regulatory and competitive pressures guide future strategies.

FAQs

What factors drive demand for IV levofloxacin formulations? Rising bacterial infections requiring hospitalization, increased use of IV antibiotics, and hospital treatment protocols.

How are pricing trends changing across regions? Prices decrease in mature markets due to generic competition but remain higher in regions with limited generic penetration or regulatory restrictions.

What is the impact of patent expiries? Patent expirations increase generic availability, reducing prices but also intensify competition.

Which regions show the highest growth potential? Asia-Pacific, driven by expanding healthcare infrastructure and rising infection rates.

What R&D directions are most promising? Developing formulations with extended shelf life, better stability in plastic containers, and fewer adverse effects.

---

References

[1] MarketWatch. (2023). Levofloxacin market report. Retrieved from https://www.marketwatch.com

[2] GlobalData. (2023). Pharmaceutical industry analysis. Retrieved from https://www.globaldata.com

[3] FDA. (2022). Guidances on sterile drug manufacturing. Retrieved from https://www.fda.gov